
Did you know only 20% of people with diabetes have all three common conditions under control: A1c, blood pressure and cholesterol? One of the big reasons is medication adherence.
read more →
Did you know only 20% of people with diabetes have all three common conditions under control: A1c, blood pressure and cholesterol? One of the big reasons is medication adherence.
read more →
The newest classes of diabetes meds to treat type 2 are pulling more than double duty, helping to better control blood sugars, protect the heart, lower body weight and prevent chronic kidney disease.
read more →
SGLT-2 Inhibitors including Invokana (canagliflozin), Farxiga (dapagliflozin), Jardiance (empagliflozin) and Steglatro (ertugliflizin), are the newest class of oral medications for the treatment of type 2 diabetes. They’re generally well tolerated and associated with significant weight loss compared with other type 2 oral meds, but there are still precautions to consider.
read more →
The use of DPP-4 inhibitors (Januvia, Onglyza, Tradjenta and Nesina) has been so widespread because these medications come in a pill, only need to be taken once a day and have few side effects.
read more →
Insulin sensitizers represent an important class of oral medications for the treatment of type 2 diabetes and work mainly by reducing insulin resistance, but a false scare with rosiglitatone led to prescribing changes for many healthcare providers.
read more →